Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to investigate the pathophysiological mechanism of omalizumab in patients with documented chronic urticaria who have complaints under standard antihistamine treatment. With this study the investigators will assess the correlation between Fc-IgE receptor downregulation as well as functionality and clinical response to omalizumab treatment in patients with chronic urticaria. This may be an approach for other diseases as well, where Fc-IgE receptor crosslinking are essential. The treatment time is set for a total of 4 monthly applications of omalizumab. According to the dosage recommendations of recent studies, fixed doses of 300 mg omalizumab are administered subcutaneously.


Clinical Trial Description

Background

Chronic urticaria (CU) is a frequent disease with a lifetime incidence of up to 25-30% of the population. Currently, CU treatment relies mainly on second generation antihistamines and is purely symptomatic. The disease tends to have a cyclical nature with spontaneous disappearance and frequent relapses. Some patients show a sufficient response to standard second generation antihistamines like (levo)cetirizine 10mg, (des)loratadine 5mg or terfenadine 120-180mg. Others need higher doses (up to 4-fold usual daily dose), often accompanied by sedation. Treatment may last for months, even years. If this first-line therapy is insufficient, the next step (sometimes even before use of excessively high doses of antihistamines) is to add first generation, even more sedating antihistamines, some of which have additional modes of action (e.g. anticholinergic effects in doxepin treatment). A considerable number of patients with CU need treatment escalations with leukotriene receptor blocking agents (e.g. montelukast), systemic corticosteroids (5-20mg prednisolon/d) or even cyclosporine (daily dose 3-5 mg/kg) or other immunosuppressive drugs used off-label. Such patients are often investigated more in detail to find an infection or autoimmune disease - often still without clear results.

Different clinical findings suggest that the mast cell system in many patients with CU is "overactive" with increased releasability. Minor stress like scratching can already induce degranulation resulting in wheal-and-flare skin reactions. Therefore, a therapy directly aiming at a decrease in this mast cell "hyperreleasability" would be optimal. Omalizumab binds selectively to free IgE in plasma, inhibits its binding to Fc-IgE receptor on the surface of mast cells and basophils and reduces the number of Fc-IgE receptors on basophils in atopic patients. Significant reduction of Fc-IgE receptor density on the surface of circulating basophils has been found as early as 1 week after administration of omalizumab. In contrast to this, the onset of clinical efficacy of omalizumab in asthma is considered to take place relatively late, namely about 4 months after start of treatment. The pathophysiologic concepts of omalizumab treatment in allergic asthma are focused on the neutralisation of IgE, and less on the Fc-IgE receptor density. In allergology, free IgE in plasma is only relevant regarding Fc-IgE receptor density on effector cells. Therefore, Fc-IgE receptor density measurement might be an important parameter for mast cell and basophil "releasability" and therefore a good in vitro surrogate marker for their reactivity. E.g. it is well known that only about 50% of IgE-sensitized individuals show clinically relevant allergic symptoms. This difference between sensitization and allergy may also be due to Fc-IgE receptor density on mast cells and basophils. Flowcytometric determination of Fc-IgE receptor density on the surface of basophils and additional testing for the functional consequences of a change in this density (ability to crosslink Fc-IgE receptors by autoantibodies and allergens) raise the possibility to evaluate this hypothesis - using omalizumab as a drug being able to decrease Fc-IgE receptor density:

1. Study data show that a fixed dose of 300 mg omalizumab is useful for the treatment of CU. The investigators assume that this effect is due to the decrease of Fc-IgE receptor density. Thus, the basophil Fc-IgE receptor density should be monitored quantitatively and functionally (see below) and correlated to clinical response.

2. 30-40% of patients with CU have autoantibodies against Fc-IgE receptor or IgE itself, which can be measured in vitro (already via ELISA, flowcytometric via CD63 and CD203c upregulation on basophils). Decrease of Fc-IgE receptor density may decrease basophil reactivity and explain or be correlated to the clinical response in CU patients. At least three patients will be followed for reactivity to autoantibodies over the study period.

3. Some patients with CU may also have an accompanying IgE-mediated allergy, which is most probably irrelevant for the CU, but offers the possibility of a functional test of basophil responsiveness to low concentrations of allergens - before (with presumably high Fc-IgE receptor density) and after omalizumab treatment (low Fc-IgE rec. density). At least three patients will be followed for allergen reactivity of basophils.

Objective

Primary objectives

− Measurement of the kinetic of Fc-IgE receptor density change on basophils from patients with chronic urticaria with omalizumab compared to placebo

Secondary objectives

- Change of responsiveness to Fc-IgE cross-linking dependent stimuli:

- incubation of patient's basophils with anti-IgE

- allergen induced cross-linking (only grass pollen and birch pollen allergic patients)

- comparison of serum on third party basophils

- Measurement of IL-3 hyperresponsiveness of basophils after Stimulation with anti-IgE and allergen

- Daily urticaria activity score

- Medication and rescue medication use

- German version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL)

Methods

This is a monocentric, double-blind, randomized placebo-controlled trial, which aims to investigate the pathophysiological mechanism of omalizumab in patients with documented chronic urticaria who have complaints under standard antihistamine treatment.

According to the inclusion criteria, 30 patients with diagnosed chronic urticaria will be recruited in our outpatient clinic. Omalizumab (Xolair®) is administered in fixed dose of 300 mg in a total of 4 monthly doses according to the reference. A follow-up visit is planned 2 months after the last injection. ;


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science


Related Conditions & MeSH terms


NCT number NCT01803763
Study type Interventional
Source University Hospital Inselspital, Berne
Contact
Status Completed
Phase Phase 2/Phase 3
Start date September 2012
Completion date March 2014

See also
  Status Clinical Trial Phase
Recruiting NCT06077773 - Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria Phase 2
Completed NCT04538794 - A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria Phase 1
Recruiting NCT05298215 - A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria Phase 2
Terminated NCT04612725 - A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO) Phase 2
Active, not recruiting NCT05528861 - A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria Phase 2
Completed NCT04109313 - An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU Phase 2
Completed NCT03580356 - A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. Phase 3
Active, not recruiting NCT05795153 - A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks. Phase 3
Completed NCT03580369 - A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines Phase 3
Completed NCT05030311 - A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines Phase 3
Recruiting NCT06162728 - Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU) Phase 1/Phase 2
Active, not recruiting NCT05107115 - Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine Phase 2
Recruiting NCT06042478 - A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients. Phase 3
Terminated NCT04159701 - A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria Phase 2
Completed NCT03749135 - Dupilumab in Chronic Spontaneous Urticaria Phase 2
Completed NCT02649218 - A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients Phase 2
Active, not recruiting NCT05368285 - A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria Phase 2
Completed NCT05373355 - Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria. Phase 1
Not yet recruiting NCT06250400 - Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU) Phase 4
Completed NCT03926611 - This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines Phase 2